<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03589378</url>
  </required_header>
  <id_info>
    <org_study_id>SZLY2017007</org_study_id>
    <secondary_id>20173357201815</secondary_id>
    <nct_id>NCT03589378</nct_id>
  </id_info>
  <brief_title>Therapeutic Plasma Exchange Adsorption Diafiltration</brief_title>
  <acronym>PEAF</acronym>
  <official_title>Efficacy of PEAF for Septic Shock With Multiple Organ Dysfunction Syndrome in ICU:A Multicenter,Open-Parallelled ,Randomized and Controlled Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shenzhen Second People's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shenzhen Second People's Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy of coupled therapeutic plasma exchange
      adsorption diafiltration (PEAF )for treating septic shock with multiple organ dysfunction
      syndrome patients in ICU.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Septic shock with multiple organ dysfunction syndrome (MODS) is a life-threatening clinical
      condition due to coagulant disorder immunoparalysis to infection. For this reason the
      extracorporeal therapies for the treatment of septic shock with MODS have become widespread
      in the ICU and, at the same time, new extracorporeal depurative techniques have been
      developed for the removal of inflammatory mediators. One of these techniques is therapeutic
      plasma exchange (TPE) that remove pathologically elevated cytokines and simultaneously to
      replace protective plasmatic factors. other techniques is coupled plasma-filtration
      adsorption (CPFA) that uses a sorbent once the separation between plasma and blood has been
      obtained with a plasma filter. The others is Plasma dialysis filtration(PDF) that can remove
      inflammatory mediators for patients with multiple organ dysfunction syndrome.The purpose of
      this study is to evaluate the efficacy of PEAF (coupled therapeutic plasma exchange
      adsorption diafiltration )for treating septic shock with multiple organ dysfunction syndrome
      patients in ICU.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 13, 2018</start_date>
  <completion_date type="Anticipated">September 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>a Multicenter,Randomized and Controlled Clinical Trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>All-cause mortality within 28 days after randomization</measure>
    <time_frame>28 days after randomization</time_frame>
    <description>efficacy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality within 90 days from randomization</measure>
    <time_frame>90 days from randomization</time_frame>
    <description>efficacy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>free hours of vasoactive drugs from randomization</measure>
    <time_frame>14 days after randomization</time_frame>
    <description>efficacy</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">168</enrollment>
  <condition>Septic Shock</condition>
  <condition>Multiple Organ Dysfunction Syndrome</condition>
  <arm_group>
    <arm_group_label>PEAF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention group:the patient will receive treatment with PEAF immediately after randomization.PEAF that is TPE (20ml/kg/d Fresh frozen plasma, Blood pump: 120ml/min, replacement pump 20ml/kg/min, dialysate pump 0ml/kg/min, waste pump 20ml/kg/min, plasma exchange 1 hour) plus plasma-filtration adsorption(PFA) (Blood pump: 120ml/min, Plasma separation rate 25-30%, PFA with acute multitherapeutic system (AMPLYA™ Italy) ≥30ml/min) and High volume plasma diafiltration (HVPDF) with CUREFLO™(ACF180W Japan) or Ultraflux® (AV1000S Fresenius Germany) , Blood pump same as PFA , replacement fluid pump 2000ml/h, dialysate pump 2000ml/h, waste pump 4000ml/h),with PFA and HVPDF for 15 hours in the first 3 days. If hemodynamically unstable or acute kidney injury(AKI) stage 2or 3,continue High volume hemofiltration(HVHF).Same protocol with control group after 3days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>HVHF for septic shock with MODS is permitted in Control group routinely（Blood pump: 200ml/min, replacement fluid pump 45ml/kg/min, dialysate pump 45ml/kg/min, waste pump 90ml/kg/min, and high-volume hemofiltration for 16 hours with CUREFLO™(ACF180W Japan) or Ultraflux® (AV1000S Fresenius Germany) in the first 3 days after randomization.If hemodynamically unstable or AKI stage 2or 3,continue HVHF.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>PEAF</intervention_name>
    <description>PEAF that is therapeutic plasma exchange (TPE) with 20ml/kg/d Fresh frozen plasma (Blood pump: 120ml/min, replacement pump 20ml/kg/min, dialysate pump 0ml/kg/min, waste pump 20ml/kg/min, plasma exchange 1 hour) plus plasma filtration adsorption (PFA ) with acute multitherapeutic system( AMPLYA™ ITALY) ≥30ml/min lasting 15 hours plus High volume plasma diafiltration (HVPDF) with CUREFLO™(ACF180W Japan) or Ultraflux® (AV1000S Fresenius Germany) Blood pump: 120ml/min, replacement fluid pump 2000ml/h, dialysate pump 2000ml/h, waste pump 4000ml/h,and with high-volume plasma diafiltration for 15 hours）in the first 3 days. the treatment after three days later is same as the control group.</description>
    <arm_group_label>PEAF</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age, gender: 18-75 years old, male or female;

          2. basic conditions: 20 ≤ APACHE II score ≤ 35 points and 10 ≤ Sequential Organ Failure
             Assessment(SOFA)≤ 18 points;

          3. septic shock : On the basis of sepsis, after adequate fluid resuscitation, sustained
             hypotension requires maintenance of vasoactive drugs, mean arterial pressure（MAP）≥ 60
             mmHg and Lactate ≥ 2.0 mmol/L; MODS: if the patient's SOFA score is ≥2 points, it
             means there is organ dysfunction. When the patient has two or more organ dysfunctions,
             it is MODS.

        Exclusion Criteria:

          1. can not remove the cause (surgical patients refused surgery, pan drug resistant
             infection without drug use)

          2. Allergic to AMPLYA™ series

          3. Presence of relative or absolute contraindications to PFA

          4. MODS caused by severe liver disease

          5. malignant tumors

          6. Chronic end-stage disease (predicted to survive no more than one month)

          7. Maternal and possibly pregnant women

          8. participated in drug clinical trials within three months

          9. Admission from an other ICU where the patient remained for more than 24 hours
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ming Wu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shenzhen Second People's Hospita</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ming Wu, MD</last_name>
    <phone>+86-0755-83366388</phone>
    <email>boshiyy@126.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yongwen Feng</last_name>
    <phone>+86-0755-83366388</phone>
    <email>fengyongwen2008@126.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Dongguan Fifth People's Hospital (Taiping Hospital)</name>
      <address>
        <city>Dongguan</city>
        <state>Guang Dong</state>
        <zip>511761</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yi Chen, MD Ph.D</last_name>
      <phone>+86-0769-85010257</phone>
      <email>chenyi_icu@163.com</email>
    </contact>
    <investigator>
      <last_name>Yi Chen, MD Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Guangzhou General Hospital of Guangzhou Military Region</name>
      <address>
        <city>Guangzhou</city>
        <state>Guang Dong</state>
        <zip>510010</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Huansheng Tong, MD Ph.D</last_name>
      <phone>+86-020-88653353</phone>
      <email>fimmuths@163.com</email>
    </contact>
    <investigator>
      <last_name>Huansheng Tong, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>School of Public Health, Southern Medical University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guang Dong</state>
        <zip>510515</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Shengli Zhang, Ph.D</last_name>
      <phone>+86-020-61648311</phone>
      <email>asl0418@126.com</email>
    </contact>
    <investigator>
      <last_name>Shengli Zhang, Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shenzhen Luohu People's hospitial</name>
      <address>
        <city>Shenzhen</city>
        <state>Guang Dong</state>
        <zip>518001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mian Peng, MD</last_name>
      <phone>+86-0755-25650005</phone>
      <email>1031994903@qq.com</email>
    </contact>
    <investigator>
      <last_name>Mian Peng, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shenzhen People's Hospital</name>
      <address>
        <city>Shenzhen</city>
        <state>Guang Dong</state>
        <zip>518020</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Huaisheng Chen, MD</last_name>
      <phone>+86-0755-25533018</phone>
      <email>sunshinic@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Huaisheng Chen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The eighth affiliated hospital, Sun Yat-Sen university</name>
      <address>
        <city>Shenzhen</city>
        <state>Guang Dong</state>
        <zip>518033</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hao LI, MD</last_name>
      <phone>+86-0755-83982222</phone>
      <email>snapzero@163.com</email>
    </contact>
    <investigator>
      <last_name>Hao LI, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Peking University Shenzhen Hospital</name>
      <address>
        <city>Shenzhen</city>
        <state>Guang Dong</state>
        <zip>518036</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lei Huang, MD</last_name>
      <phone>+86-0755-83923333</phone>
      <email>hl0248@outlook.com</email>
    </contact>
    <investigator>
      <last_name>Lei Huang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shenzhen Sixth People's Hospital (Nanshan Hospital)</name>
      <address>
        <city>ShenZhen</city>
        <state>Guang Dong</state>
        <zip>518052</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>JING lan Wu, MD</last_name>
      <phone>+86-0755-26553111</phone>
      <email>doctorwu99@126.com</email>
    </contact>
    <investigator>
      <last_name>JING lan Wu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Affiliated Baoan Hospital of Shenzhen, Southern Medical University (People' hospital of Baoan District)</name>
      <address>
        <city>Shenzhen</city>
        <state>Guang Dong</state>
        <zip>518101</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Baojun Yu, MD</last_name>
      <phone>+86-0755-27788311</phone>
      <email>ybjhb@163.com</email>
    </contact>
    <investigator>
      <last_name>Baojun Yu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shenzhen Longgang Central Hospital</name>
      <address>
        <city>Shenzhen</city>
        <state>Guang Dong</state>
        <zip>518116</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ronglin Chen, MD</last_name>
      <phone>+86-0755-84806933</phone>
      <email>13510156528@126.com</email>
    </contact>
    <investigator>
      <last_name>Ronglin Chen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shenzhen hospital of southern medicial university</name>
      <address>
        <city>Shenzhen</city>
        <state>Guang Dong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yong Liu, MD</last_name>
      <phone>+86-0755-23329999</phone>
      <email>liuyongjoy@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Yong Liu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shenzhen Second People's Hospital</name>
      <address>
        <city>Shenzhen</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ming Wu, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Schwartz J, Padmanabhan A, Aqui N, Balogun RA, Connelly-Smith L, Delaney M, Dunbar NM, Witt V, Wu Y, Shaz BH. Guidelines on the Use of Therapeutic Apheresis in Clinical Practice-Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Seventh Special Issue. J Clin Apher. 2016 Jun;31(3):149-62. doi: 10.1002/jca.21470. Review.</citation>
    <PMID>27322218</PMID>
  </reference>
  <results_reference>
    <citation>Livigni S, Bertolini G, Rossi C, Ferrari F, Giardino M, Pozzato M, Remuzzi G; GiViTI: Gruppo Italiano per la Valutazione degli Interventi in Terapia Intensiva (Italian Group for the Evaluation of Interventions in Intensive Care Medicine) is an independent collaboration network of Italian Intensive Care units. Efficacy of coupled plasma filtration adsorption (CPFA) in patients with septic shock: a multicenter randomised controlled clinical trial. BMJ Open. 2014 Jan 8;4(1):e003536. doi: 10.1136/bmjopen-2013-003536.</citation>
    <PMID>24401721</PMID>
  </results_reference>
  <results_reference>
    <citation>Colomina-Climent F, Giménez-Esparza C, Portillo-Requena C, Allegue-Gallego JM, Galindo-Martínez M, Mollà-Jiménez C, Antón-Pascual JL, Rodríguez-Serra M, Martín-Ruíz JL, Fernández-Arroyo PJ, Blasco-Císcar EM, Cánovas-Robles J, Herrera-Murillo M, González-Hernández E, Sánchez-Morán F, Solera-Suárez M, Torres-Tortajada J, Nuñez-Martínez JM, Martín-Langerwerf D, Herrero-Gutiérrez E, Sebastián-Muñoz I, Palazón-Bru A, Gil-Guillén VF. Mortality Reduction in Septic Shock by Plasma Adsorption (ROMPA): a protocol for a randomised clinical trial. BMJ Open. 2016 Jul 12;6(7):e011856. doi: 10.1136/bmjopen-2016-011856.</citation>
    <PMID>27406647</PMID>
  </results_reference>
  <results_reference>
    <citation>Franchi M, Giacalone M, Traupe I, Rago R, Baldi G, Giunta F, Forfori F. Coupled plasma filtration adsorption improves hemodynamics in septic shock. J Crit Care. 2016 Jun;33:100-5. doi: 10.1016/j.jcrc.2016.02.005. Epub 2016 Feb 15.</citation>
    <PMID>26975736</PMID>
  </results_reference>
  <results_reference>
    <citation>Hazzard I, Jones S, Quinn T. Coupled plasma haemofiltration filtration in severe sepsis: systematic review and meta-analysis. J R Army Med Corps. 2015 Dec;161 Suppl 1:i17-i22. doi: 10.1136/jramc-2015-000552. Review.</citation>
    <PMID>26621809</PMID>
  </results_reference>
  <results_reference>
    <citation>Yaroustovsky M, Abramyan M, Krotenko N, Popov D, Plyushch M, Rogalskaya E. A pilot study of selective lipopolysaccharide adsorption and coupled plasma filtration and adsorption in adult patients with severe sepsis. Blood Purif. 2015;39(1-3):210-7.</citation>
    <PMID>25765778</PMID>
  </results_reference>
  <results_reference>
    <citation>Zhou N, Li J, Zhang Y, Lu J, Chen E, Du W, Wang J, Pan X, Zhu D, Yang Y, Chen Y, Cao H, Li L. Efficacy of coupled low-volume plasma exchange with plasma filtration adsorption in treating pigs with acute liver failure: A randomised study. J Hepatol. 2015 Aug;63(2):378-87. doi: 10.1016/j.jhep.2015.03.018. Epub 2015 Mar 24.</citation>
    <PMID>25814048</PMID>
  </results_reference>
  <results_reference>
    <citation>Berlot G, Agbedjro A, Tomasini A, Bianco F, Gerini U, Viviani M, Giudici F. Effects of the volume of processed plasma on the outcome, arterial pressure and blood procalcitonin levels in patients with severe sepsis and septic shock treated with coupled plasma filtration and adsorption. Blood Purif. 2014;37(2):146-51. doi: 10.1159/000360268. Epub 2014 Apr 26.</citation>
    <PMID>24777037</PMID>
  </results_reference>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>April 22, 2018</study_first_submitted>
  <study_first_submitted_qc>July 4, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 17, 2018</study_first_posted>
  <last_update_submitted>August 27, 2018</last_update_submitted>
  <last_update_submitted_qc>August 27, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 29, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Shock, Septic</mesh_term>
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Multiple Organ Failure</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>May 18, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/78/NCT03589378/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 18, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/78/NCT03589378/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

